Geoffrey von Maltzahn

Geoffrey von Maltzahn has a diverse work experience in the life sciences industry. Geoffrey is currently a General Partner at Flagship Pioneering, a company that develops innovative life sciences ventures. In 2022, they became the Founding CEO of Quotient Therapeutics, a company focused on studying genetic variation and developing transformative medicines. Geoffrey is also the Founding CEO and Chairman of the Board at Tessera Therapeutics, a company pioneering Gene Writing™ to cure diseases at their source. Geoffrey has held leadership roles in several other companies, including Generate Biomedicines, Indigo, Sana Biotechnology, Cobalt Biomedicine, Kaleido Biosciences, Seres Therapeutics, and Axcella Health, where they contributed to the development of groundbreaking therapies and technologies.

Geoffrey von Maltzahn pursued their education in the field of engineering and biomedical sciences. Starting from 1999 to 2003, they attended the Massachusetts Institute of Technology, where they obtained a Bachelor of Science (SB) degree in Chemical Engineering. Following this, from 2003 to 2005, they enrolled at the University of California, San Diego, and earned a Master of Science (MS) degree in Bioengineering. Lastly, between 2005 and 2010, Geoffrey von Maltzahn returned to the Massachusetts Institute of Technology to pursue a Doctor of Philosophy (PhD) degree in Biomedical Engineering and Medical Physics.